Reply to Aljabali et al. Comment on “Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Medicina</i> 2022, <i>58</i>, 213”
We appreciate Ahmed Sami Aljabali and his colleagues for their interest and comments [...]
Main Authors: | Basel Abdelazeem, Kirellos Said Abbas, James Robert Brašić |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/58/6/793 |
Similar Items
-
Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Medicina</i> 2022, <i>58</i>, 213
by: Ahmed Aljabali, et al.
Published: (2022-06-01) -
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Kirellos Said Abbas, et al.
Published: (2022-02-01) -
Nusinersen for spinal muscular atrophy
by: Claudia D. Wurster, et al.
Published: (2018-03-01) -
Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
by: Andrada Mirea, et al.
Published: (2021-11-01) -
Nusinersen and spinal muscular atrophies: Where are we in 2020?
by: Satish V Khadilkar, et al.
Published: (2020-01-01)